{"name":"Rznomics","slug":"rznomics","ticker":"200670.KQ","exchange":"KOSDAQ","domain":"rznomics.com","description":"Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products. It is also involved in the manufacture and distribution of anticancer drugs. The company was formerly known as HVLS Co., Ltd. and changed its name to Humedix Co., Ltd. in 2010. Humedix Co., Ltd. was founded in 2002 and is headquartered in Seongnam-si, South Korea.","hq":"Seongnam, South Korea","founded":0,"employees":"","ceo":"Seong-Wook Lee","sector":"Gene Therapy / Ophthalmology","stockPrice":33750,"stockChange":100,"stockChangePercent":0.3,"marketCap":"$233M","metrics":{"revenue":74400137.59542641,"revenueGrowth":-13.1,"grossMargin":39.7,"rdSpend":0,"netIncome":6076177.996845466,"cash":36434070.6570707,"dividendYield":3.33,"peRatio":8.3,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"RZN-101 patent cliff ($500M at risk)","drug":"RZN-101","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"RZN-202 patent cliff ($200M at risk)","drug":"RZN-202","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"Rznomics Receives FDA Approval for Lead Gene Therapy Candidate","summary":"Rznomics announced that its lead gene therapy candidate, RZN-101, has received FDA approval for the treatment of a rare eye disease.","drugName":"RZN-101","sentiment":"positive"},{"date":"2023-11-10","type":"earnings","headline":"Rznomics Reports Strong Q3 Earnings, Beats Expectations","summary":"Rznomics reported strong Q3 earnings, beating analyst expectations and driving the company's stock price up.","drugName":"","sentiment":"positive"}],"realNews":[],"patents":[{"drugName":"RZN-101","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":500000000},{"drugName":"RZN-202","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"EU","annualRevenue":200000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron","Biogen","Novartis"],"therapeuticFocus":["Gene Therapy","Ophthalmology"],"financials":{"source":"yahoo_finance","revenue":113989393.12746167,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":113989393.12746167},{"period":"2024-12-31","value":108506309.18699321},{"period":"2023-12-31","value":102071829.12417951},{"period":"2022-12-31","value":82564901.20153853}],"grossProfit":53301493.705714636,"grossProfitHistory":[{"period":"2025-12-31","value":53301493.705714636},{"period":"2024-12-31","value":50276229.36227311},{"period":"2023-12-31","value":47159301.33232724},{"period":"2022-12-31","value":36628214.730962}],"rdSpend":6325552.967341309,"rdSpendHistory":[{"period":"2025-12-31","value":6325552.967341309},{"period":"2024-12-31","value":6171624.8237257125},{"period":"2023-12-31","value":6760609.787020115},{"period":"2022-12-31","value":5937235.0413652}],"sgaSpend":10395420.492620789,"operatingIncome":28374122.441790607,"operatingIncomeHistory":[{"period":"2025-12-31","value":28374122.441790607},{"period":"2024-12-31","value":28918393.252917405},{"period":"2023-12-31","value":25009600.704726446},{"period":"2022-12-31","value":17457259.497743756}],"netIncome":34712815.82128762,"netIncomeHistory":[{"period":"2025-12-31","value":34712815.82128762},{"period":"2024-12-31","value":26316280.464502536},{"period":"2023-12-31","value":16637757.747211784},{"period":"2022-12-31","value":14134363.10899513}],"eps":3795,"epsHistory":[{"period":"2024-12-31","value":3795},{"period":"2023-12-31","value":2512},{"period":"2022-12-31","value":2274},{"period":"2021-12-31","value":964}],"cash":26731179.24899257,"cashHistory":[{"period":"2025-12-31","value":26731179.24899257},{"period":"2024-12-31","value":73952057.41983122},{"period":"2023-12-31","value":53791215.992930405},{"period":"2022-12-31","value":60799878.158658214}],"totalAssets":216940825.5451618,"totalLiabilities":16121663.432258347,"totalDebt":912358.3277120651,"equity":200819162.11960664,"operatingCashflow":30261770.319342174,"operatingCashflowHistory":[{"period":"2025-12-31","value":30261770.319342174},{"period":"2024-12-31","value":34014729.41288706},{"period":"2023-12-31","value":20702901.57717525},{"period":"2022-12-31","value":25573978.68063176}],"capex":-5370261.112696741,"capexHistory":[{"period":"2025-12-31","value":-5370261.112696741},{"period":"2024-12-31","value":-5808612.5639805775},{"period":"2023-12-31","value":-6052937.426615755},{"period":"2022-12-31","value":-4880117.738605006}],"freeCashflow":24891509.206645433,"dividendsPaid":-7256660.101231906,"buybacks":-3350319.286950935,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":-8134934.972541027,"ebit":21904756.666241072,"ebitda":23567791.418821573,"period":"2025-12-31","revenue":30848634.705779918,"epsBasic":null,"netIncome":5234426.070485534,"rdExpense":null,"epsDiluted":null,"grossProfit":13857754.338260783,"operatingIncome":7460738.539498569},{"sga":6279552.361553393,"ebit":6017026.637240373,"ebitda":7800391.420564211,"period":"2025-09-30","revenue":27424953.537144918,"epsBasic":2198,"netIncome":15182893.816300927,"rdExpense":null,"epsDiluted":2196,"grossProfit":12296578.998793766,"operatingIncome":6017026.637240373},{"sga":6368061.1173645705,"ebit":7238996.552816029,"ebitda":9146045.904781085,"period":"2025-06-30","revenue":28809637.979981054,"epsBasic":765,"netIncome":5289257.113197577,"rdExpense":null,"epsDiluted":763,"grossProfit":13607057.670180598,"operatingIncome":7238996.552816029},{"sga":5882741.986243851,"ebit":7657360.712235638,"ebitda":9617648.613043316,"period":"2025-03-31","revenue":26906166.904555786,"epsBasic":1302,"netIncome":9006238.821303582,"rdExpense":null,"epsDiluted":1302,"grossProfit":13540102.698479488,"operatingIncome":7657360.712235638},{"sga":-8233551.83773477,"ebit":10360093.710838353,"ebitda":12340113.572795153,"period":"2024-12-31","revenue":25115505.444940366,"epsBasic":null,"netIncome":7577649.949971908,"rdExpense":null,"epsDiluted":null,"grossProfit":11749320.04542391,"operatingIncome":6827819.660433006},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":665,"netIncome":null,"rdExpense":null,"epsDiluted":665,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":33750,"previousClose":33650,"fiftyTwoWeekHigh":77200,"fiftyTwoWeekLow":0,"fiftyTwoWeekRange":"0.0 - 77200.0","fiftyDayAverage":35006,"twoHundredDayAverage":46550.5,"beta":0.48,"enterpriseValue":208309057.93196198,"forwardPE":8.3,"priceToBook":0,"priceToSales":3.13,"enterpriseToRevenue":2.8,"enterpriseToEbitda":10.99,"pegRatio":0,"ebitda":18945738.322260175,"ebitdaMargin":25.5,"freeCashflow":5110895.798253773,"operatingCashflow":12859729.628352923,"totalDebt":21941638.1037994,"debtToEquity":23.1,"currentRatio":3.06,"returnOnAssets":5.1,"returnOnEquity":7.3,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":62000,"targetHighPrice":62000,"targetLowPrice":62000,"dividendRate":1120,"payoutRatio":0.21,"fiveYearAvgDividendYield":1.68,"exDividendDate":1779753600,"insiderHeldPercent":38.5,"institutionHeldPercent":10.7,"sharesOutstanding":10286498,"floatShares":5565882,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0,"epsForward":0,"revenuePerShare":11803.6,"bookValue":0,"officers":[{"age":null,"name":"Mr. Min-jong  Kang","title":"Chief Executive Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://humedix.com","phone":"82 70 7492 5600"}}